Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2–3 randomised trial
<p>Background: There has been a significant change in trials methodology for solid tumours, in response to our greater understanding of cancer biology. FOCUS4 is a phase II/III trial programme testing targeted agents in patients with advanced colorectal cancer (CRC) in molecularly stratified c...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Published: |
Elsevier
2017
|